Table 5. Results of the probabilistic sensitivity analysis.

	Current situation	95% CI	New situation	95% CI
Scenario 1: QIV all eligible groups
TOTAL costs (direct & societal, disc.) (€)	462,963,000	[410,462,000; 526,877,000]	469,429,000	[420,261,000; 528,359,000]
Total number of hospitalizations	50,630	[44,800; 57,400]	47,480	[42,000; 53,700]
Total number of deaths	2,920	[2,530; 3,320]	2,730	[2,370; 3,100]
Scenario 2: QIV <65y
TOTAL costs (direct & societal, disc.) (€)	462,508,000	[414,574,000; 532,754,000]	461,826,000	[414,302,000; 531,372,000]
Total number of hospitalizations	50,790	[44,900; 57,700]	50,340	[44,500; 57,200]
Total number of deaths	2,920	[2,540; 3,380]	2,900	[2,510; 3,350]
Scenario 3: QIV +65y
TOTAL costs (direct & societal, disc.) (€)	459,760,000	[415,006,000; 527,887,000]	465,658,000	[423,355,000; 530,595,000]
Total number of hospitalizations	50,880	[44,900; 56,900]	47,920	[42,300; 53,500]
Total number of deaths	2,920	[2,530; 3,310]	2,740	[2,380; 3,110]

CI: credibility intervals; QIV: quadrivalent influenza vaccine.